HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M400160-MCP200v1 3/12/1200    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fach, E. M. Articles by Opiteck, G. J. Search for Related Content PubMed PubMed Citation Articles by Fach, E. M. Articles by Opiteck, G. J. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 3:1200-1210, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

In Vitro Biomarker Discovery for Atherosclerosis by Proteomics^*

Estelle M. Fach, Leah-Ann Garulacan, Ji Gao, Qing Xiao, Stephen M. Storm, Yves P. Dubaquie, Stanley A. Hefta and Gregory J. Opiteck

From the Department of Clinical Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ 08543

The purpose of this study was to identify in vitro and then prioritize a tractable set of protein biomarker candidates of atherosclerosis that may eventually be developed to measure the extent, progression, regression, and stability of atherosclerotic lesions. A study was conducted using an in vitro"foam cell" model based on the stimulation of differentiated THP1 cells with oxidized low-density lipoprotein (oxidized LDL) as compared with low-density lipoprotein (LDL). Analysis of the proteins contained in the cell supernatant using proteome scanning technology identified 59 proteins as being increased, 57 with no statistically measurable difference, and 17 decreasing in abundance following treatment with oxidized LDL, as compared with LDL. From the up-regulated list, proteins were prioritized based on their analytical confidence as well as their relevance to atherosclerosis pathways. Within the group of increased abundance, seven families of proteins were of particular interest: fatty acid-binding proteins, chitinase-like enzymes, cyclophilins, cathepsins, proteoglycans, urokinase-type plasminogen activator receptor, and a macrophage scavenger receptor.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF]

				S. P. M. Lutgens, K. B. J. M. Cleutjens, M. J. A. P. Daemen, and S. Heeneman Cathepsin cysteine proteases in cardiovascular disease FASEB J, October 1, 2007; 21(12): 3029 - 3041. [Abstract] [Full Text] [PDF]

				C. Bagnato, J. Thumar, V. Mayya, S.-I. Hwang, H. Zebroski, K. P. Claffey, C. Haudenschild, J. K. Eng, D. H. Lundgren, and D. K. Han Proteomics Analysis of Human Coronary Atherosclerotic Plaque: A Feasibility Study of Direct Tissue Proteomics by Liquid Chromatography and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2007; 6(6): 1088 - 1102. [Abstract] [Full Text] [PDF]

				L. M. Blanco-Colio, J. L. Martin-Ventura, F. Vivanco, J.-B. Michel, O. Meilhac, and J. Egido Biology of atherosclerotic plaques: What we are learning from proteomic analysis Cardiovasc Res, October 1, 2006; 72(1): 18 - 29. [Abstract] [Full Text] [PDF]

				J. P. Conway and M. Kinter Proteomic and Transcriptomic Analyses of Macrophages with an Increased Resistance to Oxidized Low Density Lipoprotein (oxLDL)-induced Cytotoxicity Generated by Chronic Exposure to oxLDL Mol. Cell. Proteomics, October 1, 2005; 4(10): 1522 - 1540. [Abstract] [Full Text] [PDF]